• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

  • Featured Product
  • KD/KO Validated

CoraLite®555-conjugated VPRBP Polyclonal antibody

VPRBP Polyclonal Antibody for IF/ICC, FC (Intra)

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

IF/ICC, FC (Intra)

Conjugate

CoraLite®555 Fluorescent Dye

Cat no : CL555-11612

Synonyms

KIAA0800, HIV-1 Vpr-binding protein, HIV 1 Vpr binding protein, EC:2.7.11.1, DDB1- and CUL4-associated factor 1

Validation Data Gallery

Filter:
  • Immunofluorescence (IF) / fluorescent staining of HeLa cells using CoraLite®555-conjugated VPRBP Polyclonal antibody (CL555-11612)

    IF Staining of HeLa using CL555-11612

    Immunofluorescent analysis of (4% PFA) fixed HeLa cells using CoraLite®555 VPRBP antibody (CL555-11612) at dilution of 1:100, CL488-Phalloidin (green).

  • Flow cytometry (FC) experiment of HeLa cells using CoraLite®555-conjugated VPRBP Polyclonal antibody (CL555-11612)

    FC experiment of HeLa using CL555-11612

    1X10^6 HeLa cells were intracellularly stained with 0.4 ug CoraLite®555 Anti-Human VPRBP (CL555-11612) (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

☆大好評トライアルサイズ ¥20,000～！ >>> 一次抗体特別価格キャンペーン開催中！

Tested Applications

Positive IF/ICC detected inHeLa cells
Positive FC (Intra) detected inHeLa cells

Recommended dilution

ApplicationDilution
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
Flow Cytometry (FC) (INTRA)FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

CL555-11612 targets VPRBP in IF/ICC, FC (Intra) applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen VPRBP fusion protein Ag2184 相同性解析による交差性が予測される生物種
Full Name Vpr (HIV-1) binding protein
Calculated molecular weight 1506 aa, 169 kDa
Observed molecular weight 169 kDa
GenBank accession numberBC022792
Gene symbol VPRBP
Gene ID (NCBI) 9730
RRIDAB_2919603
Conjugate CoraLite®555 Fluorescent Dye
Excitation/Emission maxima wavelengths557 nm / 570 nm
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
Storage ConditionsStore at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

VprBP was first identified as a protein that can interact with HIV-1 viral protein R (PMID: 11223251). It is a component of the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex that could interact with HIV-1 virus Vpr protein and HIV-2 virus Vpx protein (PMID: 18332868; 17314515; 18606781). VprBP is a 1,507-amino acid protein that contains conserved domains, including YXXY repeats, the Lis homology motif, and WD40 repeats. Through binding to Vpr, VprBP allows Vpr to modulate the catalytic activity of the CUL4-DDB1 complex, which in turn leads to the induction of G2 phase arrest in the virus-infected cells (PMID: 17630831). Recently it has been reported that VprBP is able to regulate the p53-induced transcription and apoptotic pathway (PMID: 22184063).

Protocols

Product Specific Protocols
IF protocol for CL555 VPRBP antibody CL555-11612Download protocol
FC protocol for CL555 VPRBP antibody CL555-11612Download protocol
Standard Protocols
Click here to view our Standard Protocols